المؤلفون: Sara Faouzi, Caroline Brard, Jeremy Lupu, Isabelle Girault, Séverine Roy, Kristina Sorg, SuFey Ong, Emilie Routier, Shensi Shen, Caroline Robert, Sarah Warren, Pascale Morel, Julien Adam, Stéphan Vagner, Jean-Yves Scoazec

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Programmed Cell Death 1 Receptor, Proximity ligation assay, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Transcriptome, Internal medicine, PD-L1, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Medicine, Humans, Immune Checkpoint Inhibitors, Melanoma, biology, business.industry, medicine.disease, Ipilimumab, Progression-Free Survival, Nivolumab, Treatment Outcome, Relative risk, Cohort, biology.protein, Biomarker (medicine), business, CD8

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcb295a0dde2f241f9c9500db9895e1cTest
https://pubmed.ncbi.nlm.nih.gov/34785583Test

المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser

المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test

المؤلفون: Jonathan Cebon, Neil Steven, Mark R. Middleton, Darcy A. Hille, Erika Richtig, Céleste Lebbé, Nageatte Ibrahim, Euan Walpole, Caroline Robert, Giuseppe Masucci, Wei Zhou, Wilson H. Miller, Teresa M. Petrella

المصدر: European Journal of Cancer. 86:115-124

مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Longitudinal data, Health Status, Population, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Quality of life, Internal medicine, medicine, Humans, In patient, Patient Reported Outcome Measures, 030212 general & internal medicine, education, Melanoma, Advanced melanoma, education.field_of_study, business.industry, Eortc qlq c30, Middle Aged, humanities, Surgery, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Quality of Life, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e890ea1bf10f65d9c5dbe680fbd78ba4Test
https://doi.org/10.1016/j.ejca.2017.08.032Test

المؤلفون: Piotr Rutkowski, Lars Bastholt, Ralf Gutzmer, Claus Garbe, Virginia Ferraresi, Marta Nyakas, Omid Hamid, Joanna Pikiel, Jean-Jacques Grob, Paolo A. Ascierto, Céleste Lebbé, Caroline Robert, Delphine Hennicken, Vanna Chiarion-Sileni, Michael Smylie, Gabriella Liszkay, Florent Grange, Catriona M. McNeil, Luc Thomas, Dirk Schadendorf, Andrzej Mackiewicz, Michele Del Vecchio, Christoph Hoeller, Carmen Loquai, Michele Maio, Inge Marie Svane, Anila Qureshi, Brigitte Dréno, Ana Arance, Laurent Mortier

المساهمون: Istituto Nazionale Tumori Fondazione Pascale [Naples, Italy], Medical Oncology, National Cancer Institute [Milan, Italy], Institut Gustave Roussy ( IGR ), Department of Diagnostics and Cancer Immunology [Poznan, Poland], Greater Poland Cancer Centre [Poznan, Poland]-Poznan Medical University [Poland], Melanoma Oncology Unit [Padova, Italy], Veneto Institute of Oncology IOV-IRCCS [Padua, Italy], Institut d'Investigacions Biomèdiques August Pi I Sunyer [Barcelona, Spain] ( Hospital Clinic ), Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées ( DIO U976 ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Odense University Hospital [Odense, Denmark], The Angeles Clinic and Research Institute [Los Angeles, CA, USA], Maria Sklodowska-Curie Memorial Cancer Center [Warsaw, Poland], Royal Prince Alfred Hospital ( RPAH - SYDNEY ), Melanoma Institute Australia [Sydney, NSW, Australia], Eberhard Karls University [Tübingen, Germany], University Medical Center [Mainz, Germany], Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Département de Dermatologie [CH Lyon-Sud, Pierre-Bénite], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Hôpital de la Timone [CHU - APHM] ( TIMONE ), National Institute of Oncology [Budapest, Hungary], Oslo University Hospital [Oslo, Norway], Medizinische Hochschule Hannover [Hannover, Germany], Wojewodzkie Centrum Oncologii [Gdańsk, Poland], Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims ( CHU Reims ), Medical University of Vienna [Austria], Istituti Fisioterapici Ospitalieri [Rome, Italy], Cross Cancer Institute [Edmonton, AB, Canada], University Hospital [Essen, Germany], Hôspital Claude Huriez [Lille, France], Herlev Hospital [Herlev, Denmark], University of Copenhagen ( KU ), Bristol-Myers Squibb [Princeton, NJ, USA], Istituto Toscano Tumori [Siena, Italy], University Hospital of Siena [Italy], Bristol-Myers Squibb., Institut Gustave Roussy (IGR), Institut d'Investigacions Biomèdiques August Pi I Sunyer [Barcelona, Spain] (Hospital Clinic ), Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cedars-Sinai Medical Center, Royal Prince Alfred Hospital (RPAH - SYDNEY), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital de la Timone [CHU - APHM] (TIMONE), Oslo University Hospital [Oslo], Centre Hospitalier Universitaire de Reims (CHU Reims), Medizinische Universität Wien = Medical University of Vienna, Hôpital Claude Huriez [Lille], CHU Lille, Herlev and Gentofte Hospital, Bristol-Myers Squibb [Princeton], Bernardo, Elizabeth

المصدر: Ascierto, P A, Del Vecchio, M, Robert, C, Mackiewicz, A, Chiarion-Sileni, V, Arance, A, Lebbe, C, Bastholt, L, Hamid, O, Rutkowski, P, McNeil, C, Garbe, C, Loquai, C, Dreno, B, Thomas, L, Grob, J-J, Liszkay, G, Nyakas, M, Gutzmer, R, Pikiel, J, Grange, F, Hoeller, C, Ferraresi, V, Smylie, M, Schadendorf, D, Mortier, L, Svane, I M, Hennicken, D, Qureshi, A & Maio, M 2017, ' Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trial ', Lancet Oncology, vol. 18, no. 5, pp. 611-622 . https://doi.org/10.1016/S1470-2045Test(17)30231-0
Articles Lancet Oncol
Articles Lancet Oncol, 2017, 18 (5), pp.611-622. 〈10.1016/S1470-2045(17)30231-0〉
Lancet Oncology
Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Lancet Oncology, Elsevier, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩

مصطلحات موضوعية: Male, 0301 basic medicine, Medizin, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Clinical endpoint, Melanoma, education.field_of_study, Hazard ratio, Antibodies, Monoclonal, Alanine Transaminase, Middle Aged, Colitis, Intention to Treat Analysis, 3. Good health, Survival Rate, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, medicine.drug, Diarrhea, medicine.medical_specialty, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Ipilimumab, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Internal medicine, Journal Article, medicine, Humans, Hypophysitis, Adverse effect, education, Survival rate, Aged, Intention-to-treat analysis, business.industry, Surgery, 030104 developmental biology, business, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227f341e72494aa06d0cdefaa7df2e4fTest
https://doi.org/10.1016/s1470-2045Test(17)30231-0

المؤلفون: Samy Ammari, Salima Hibat-Allah, Frédéric Dhermain, Mathieu Texier, Charlée Nardin, Caroline Robert, Christine Mateus, Emilie Lanoy

المصدر: Melanoma research. 28(2)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Population, Ipilimumab, Dermatology, Pembrolizumab, Antibodies, Monoclonal, Humanized, Radiosurgery, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, parasitic diseases, Clinical endpoint, Medicine, Humans, Neoplasm Metastasis, Prospective cohort study, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Brain Neoplasms, Melanoma, Chemoradiotherapy, Middle Aged, medicine.disease, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf47e8d5161bd7b7d968441998e4af3eTest
https://pubmed.ncbi.nlm.nih.gov/29356789Test

المؤلفون: Honghong Zhou, Caroline Robert, Georgina V. Long, Gil Bar-Sela, Christoph Hoeller, Christian U. Blank, Matteo S. Carlino, Dirk Schadendorf, Catherine Barrow, Antoni Ribas, Christian Caglevic, Adil Daud, Erika Richtig, Ahmed Tarhini, Erin Jensen, Pascal Wolter, Nageatte Ibrahim, Kenneth Emancipator, Marta Nyakas, Scot Ebbinghaus

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Adolescent, Medizin, Ipilimumab, Kaplan-Meier Estimate, Pembrolizumab, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Drug Administration Schedule, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, Humans, Medicine, In patient, Clinical significance, Melanoma, Aged, Advanced melanoma, Aged, 80 and over, business.industry, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::379a23f5eaed8008bb5457e825ae223bTest
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85051002457Test

المؤلفون: Caroline Robert, Debra A. Patt, David Berman, Omid Hamid, F. Stephen Hodi, Jedd D. Wolchok, Tai-Tsang Chen, Jeffrey S. Weber, Kim Margolin, Dirk Schadendorf

المصدر: Journal of Clinical Oncology. 33:1889-1894

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Medizin, Antineoplastic Agents, Ipilimumab, Kaplan-Meier Estimate, Drug Administration Schedule, Clinical Trials, Phase II as Topic, Internal medicine, Humans, Medicine, Prospective Studies, Prospective cohort study, Melanoma, Survival analysis, Retrospective Studies, business.industry, Antibodies, Monoclonal, Retrospective cohort study, Surgery, Clinical trial, Treatment Outcome, Pooled analysis, Clinical Trials, Phase III as Topic, Expanded access, Meta-analysis, business, Follow-Up Studies, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c92bb84e35d91b1479086ac0b4c5af2Test
https://doi.org/10.1200/jco.2014.56.2736Test

المؤلفون: Igor Bondarenko, Jedd D. Wolchok, Jean-Jacques Grob, Alessandro Testori, Claus Garbe, Luc Thomas, Michele Maio, Tai-Tsang Chen, Caroline Robert, Vanna Chiarion-Sileni, Steinar Aamdal, Marina Tschaika

المصدر: Journal of Clinical Oncology. 33:1191-1196

مصطلحات موضوعية: Diarrhea, Male, Cancer Research, medicine.medical_specialty, Time Factors, Dacarbazine, Vitiligo, Ipilimumab, Kaplan-Meier Estimate, Placebo, Drug Administration Schedule, law.invention, Maintenance therapy, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Original Reports, Humans, Medicine, Melanoma, Survival rate, Survival analysis, Aged, business.industry, Pruritus, Antibodies, Monoclonal, Exanthema, Middle Aged, Survival Analysis, Surgery, Survival Rate, Clinical trial, Treatment Outcome, Oncology, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dca8a4e18fdd6842dda5e19639f3617Test
https://doi.org/10.1200/jco.2014.56.6018Test

المؤلفون: Richard W. Joseph, Christine Mateus, Amita Patnaik, Roxana S. Dronca, Omid Hamid, Adil Daud, F. Stephen Hodi, Scot Ebbinghaus, Wen-Jen Hwu, Jeroen Elassaiss-Schaap, Peter D. Boasberg, Richard F. Kefford, Antoni Ribas, Tara C. Gangadhar, S. Peter Kang, Bartosz Chmielowski, Anthony M. Joshua, Jedd D. Wolchok, Caroline Robert, Kevin Gergich, Hassane M. Zarour, Xiaoyun Nicole Li, Robert Iannone, Michael A. Postow, Jeffrey S. Weber

المصدر: The Lancet. 384:1109-1117

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Skin Neoplasms, Adolescent, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, law.invention, Young Adult, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Humans, Adverse effect, Melanoma, Fatigue, Aged, Dose-Response Relationship, Drug, business.industry, Pruritus, Antibodies, Monoclonal, General Medicine, Middle Aged, Rash, Surgery, Clinical trial, Treatment Outcome, Drug Resistance, Neoplasm, Response Evaluation Criteria in Solid Tumors, Female, Drug Eruptions, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::567ff1bc306785d4655b459c1c335c52Test
https://doi.org/10.1016/s0140-6736Test(14)60958-2

المؤلفون: Christian U. Blank, Adil Daud, Rene Gonzalez, Kim Margolin, Scot Ebbinghaus, Ziwen Wei, Dirk Schadendorf, Antoni Ribas, Anna C. Pavlick, Lee D. Cranmer, Caroline Robert, April K.S. Salama, Jacob Schachter, Omid Hamid, Reinhard Dummer, Nageatte Ibrahim, F. Stephen Hodi, Igor Puzanov, Tara C. Gangadhar, Paolo A. Ascierto

المساهمون: University of Zurich, Hamid, Omid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business

وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test